Avicanna Launches Innovative Study for Osteoarthritis Relief

Avicanna Sponsors Innovative Clinical Research

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is making headlines as it embarks on an exciting journey in the realm of medical cannabis. The company has recently entered a Sponsored Research Agreement to activate a significant clinical trial focusing on the efficacy of oral cannabis extracts in alleviating osteoarthritic pain.

Overview of the Clinical Study

This study, titled “The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain,” is driven by the expertise of Dr. Hance Clarke, the medical director of the Pain Research Unit. Dr. Clarke is at the forefront of this initiative and is set to lead the trial, expected to initiate in the Fall of 2025.

Primary Objective

The primary goal of this randomized controlled trial (RCT) is to evaluate the feasibility of using oral cannabinoids to enhance pain management in patients suffering from hip and knee osteoarthritis. The study aims to determine aspects such as patient participation, adherence to protocols, and the integrity of the collected data, all of which are critical to the planning of future definitive trials.

Funding and Support

This clinical research is supported by a grant from the Canadian Institutes of Health Research (CIHR), showcasing the commitment to exploring innovative treatments within the framework of health research. Avicanna's involvement is crucial as it supplies proprietary CBD and THC capsules manufactured under Good Manufacturing Practices (GMP), which are essential for the trial.

About Avicanna: A Commitment to Health and Wellness

Avicanna stands as a pioneering biopharmaceutical company dedicated to advancing cannabinoid-based products. With a strong international presence, the firm specializes in the research, manufacturing, and commercialization of these products aimed at the medical and pharmaceutical markets.

Comprehensive Product Offerings

Avicanna's robust portfolio includes a diverse range of products under their RHO Phyto™ brand, which encompasses oral, sublingual, topical, and transdermal solutions. Each product is carefully crafted with various cannabinoid ratios, supported by ongoing education for both patients and healthcare professionals. RHO Phyto™ is currently well-established across Canada and is steadily expanding into new international markets.

Integrated Medical Care through MyMedi.ca

In addition to product development, Avicanna operates the MyMedi.ca platform, designed to enhance the experience for medical cannabis patients. This platform, run by Northern Green Canada Inc., features a broad array of products complemented by pharmacist-led patient support programs. MyMedi.ca also caters to specific groups, such as veterans, ensuring that unique patient needs are met efficiently.

Innovative Pharmaceutical Pipeline

Avicanna's pharmaceutical pipeline showcases a range of proprietary candidates specifically formulated to address various medical challenges, including dermatology, chronic pain, and neurological disorders. The emphasis on scientific innovation and integration positions the company as a leader in cannabinoid research.

Active Pharmaceutical Ingredients

The company's subsidiary, Santa Marta Golden Hemp SAS (SMGH), plays a vital role in supplying high-quality CBD, THC, and CBG to Avicanna's partners worldwide. This vertical integration ensures that Avicanna maintains reliable access to necessary components for their medical and retail products, enhancing the credibility of their offerings across global markets.

Conclusion

Avicanna Inc. is not just a player in the modern biopharmaceutical landscape but a trailblazer paving the way for new advancements in cannabinoid research and product development. As the company embarks on this new clinical study, the potential benefits for patients dealing with osteoarthritis pain could be transformative, showcasing Avicanna’s ongoing commitment to innovation and healthcare improvement.

Frequently Asked Questions

What clinical study is Avicanna sponsoring?

Avicanna is sponsoring an RCT to assess the effectiveness of oral cannabis extracts for osteoarthritic pain.

Who is leading the clinical study?

The clinical study is led by Dr. Hance Clarke, a prominent medical director in pain research.

What are the primary objectives of the study?

The primary aim is to evaluate the feasibility of using oral cannabinoids to manage pain in osteoarthritis patients.

How is the study funded?

The clinical study is financially supported by a grant from the Canadian Institutes of Health Research (CIHR).

What other initiatives does Avicanna have?

Avicanna offers a range of products and services, including a medical cannabis care platform, pharmaceutical development, and active pharmaceutical ingredients through its subsidiary, SMGH.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.